US-based Gilead Sciences had licensing agreement with seven Indian pharmaceutical companies including Hetero Labs to produce Remdesivir.
Genetek, which already produces several life-saving drugs, was granted FDA permission following the initiative of Union minister Nitin Gadkari. The proposal of Genetek to manufacture the anti-viral drug was also cleared by the drugs controller general of India earlier.
Chetan Marwah, principal correspondent of Genetek, said, “We have started procurement of raw materials, active and inactive ingredients from parent company.”
“The vials, the printing of the packages and labels too has started,” said Marwah claiming that the entire machinery was geared up for the production. “It will take around a fortnight or so to launch the product in the market. In mock runs, the production capacity may fluctuate but in the long run it would 30,000 per day. The drug would be released in the market through proper channel,” he said.
Marwah also said there would be no compromise on quality though some of the lengthier processes are likely to be shortened for a quicker release of the drugs needed to fight the pandemic. “The drug would be put through all necessary and mandatory tests and trials before release,” he said.